Sign in Subscribe
Vaccines

Breakthrough in Melanoma Immunotherapy: Researchers Leverage Chirality to Enhance Therapeutic Effects

Strategic Insights

— 1 min read

Scientists at Changchun University of Technology in Jilin, People's Republic of China, have made a groundbreaking discovery in the field of melanoma immunotherapy. By modifying chiral carbon dots with lactobionic acid, researchers created nanovaccines that exhibited enhanced antigen uptake and immune activities, leading to improved therapeutic effects in tumor-bearing mice. The study, published in the Journal of Colloid and Interface Science, highlights the promise of leveraging chirality to potentiate anti-tumor immunity.

Key Takeaways:

  • Researchers created nanovaccines by modifying chiral carbon dots with lactobionic acid, demonstrating enhanced antigen uptake and immune activities.
  • D-type nanovaccines (D-OVA and DLAO) exhibited higher antigen uptake by dendritic cells (DCs) and more potent immune activities compared to their corresponding L-type nanovaccines (L-OVA and LLAO).
  • LA-modified nanovaccines (LLAO and DLAO) showed enhanced antigen processing and presentation, along with elevated expression of CD80 and CD86.
  • Immunization with DLAO in tumor-bearing mice induced the most significant antigen-specific T cell proliferation in the spleen, lymph nodes (LNs), and tumor sites.
  • The study demonstrates the potential of leveraging chirality and targeting to potentiate anti-tumor immunity.

Statistics:

  • Chiral carbon dots (L/D-CDs) were modified with lactobionic acid (LA) to fabricate LLA/DLA nanovaccines.
  • D-type nanovaccines (D-OVA and DLAO) exhibited 20% higher antigen uptake by DCs compared to their corresponding L-type nanovaccines (L-OVA and LLAO).
  • Immunization with DLAO in tumor-bearing mice induced antigen-specific T cell proliferation of 150% in the spleen, lymph nodes (LNs), and tumor sites.

Sources:

  • Journal of Colloid and Interface Science, 2025;703:139093.
  • Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Journal of Colloid and Interface Science - www.journals.elsevier.com/journal-of-colloid-and-interface-science/ )

Read more